SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myogen (MYOG) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (20)3/6/2006 6:12:24 PM
From: tuck  Read Replies (1) | Respond to of 50
 
>>Biotechnology company Myogen Inc. topped Wall Street's consensus target for full-year earnings but the company missed analysts' sales estimate by a wide margin, sending shares lower aftermarket. The company also refrained from issuing financial guidance to review the costs and potential revenue of its drug development program.

Myogen shares dropped $4.51, or 10.9 percent, to $36.80 in extended trading. The stock closed up 33 cents to $41.31 on the Nasdaq.<<

This is a snip from AP's after hours roundup. Pretty funny how little they understand. As if earnings and revenues mattered. Guidance maybe a little. Glaxo deal = 80% of downward move, is my guess. Stock struggling to stay above $36.99 now.

Cheers, Tuck



To: tuck who wrote (20)3/8/2006 11:36:35 AM
From: kenhott  Respond to of 50
 
Whatever rkrw wrote in reply, I agree. That goes for any future comments also.

In fact, how do you know I am not rk or rw??

p.s. Life w/o broadband is tough.

p.p.s. People needed to sell in front of ENCY's event. The run up was a gift from the market.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News